Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic

Katerina V Kiburg; Glenn M Ward; David N O'Neal; Richard J MacIsaac

doi:10.1111/imj.13691

Lipid-lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic

Intern Med J. 2018 Feb;48(2):201-204. doi: 10.1111/imj.13691.

Authors

Katerina V Kiburg^{1

2}, Glenn M Ward^{1

3}, David N O'Neal^{1

3}, Richard J MacIsaac^{1

3}

Affiliations

¹ Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
² Department of Endocrinology and Diabetes, St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.
³ Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

PMID: 29415350
DOI: 10.1111/imj.13691

Abstract

We documented temporal changes in the use of lipid-lowering medications and achievement of cholesterol targets in an Australian diabetes clinic. The number of patients using lipid-lowering therapy for primary or secondary cardiovascular prevention increased from 6 to 69% between 1993-1995 and 2014-2016, which corresponded to a decrease in low-density lipoprotein cholesterol levels from 3.7 to 2.4 mmol/L (P < 0.01).

Keywords: cardiovascular disease; cholesterol; diabetes; endocrinology; lipid-lowering therapy.

MeSH terms

Adult
Aged
Aged, 80 and over
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use*
Cardiovascular Diseases / blood
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / blood
Cholesterol, LDL / drug effects*
Diabetes Mellitus / blood
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / epidemiology
Female
Humans
Hypercholesterolemia / blood
Hypercholesterolemia / drug therapy*
Hypercholesterolemia / epidemiology
Male
Middle Aged
Primary Prevention / methods
Secondary Prevention / methods
Victoria / epidemiology

Substances

Anticholesteremic Agents
Cholesterol, LDL